{"ctNumber":"2022-500596-32-00","ctStatus":"Authorised","startDateEU":"2024-10-01","decisionDate":"2022-06-22T13:44:32.4","publishDate":"2025-12-03T02:32:30.801653802","ctPublicStatusCode":4,"authorizedApplication":{"authorizedPartI":{"id":102812,"rowSubjectCount":0,"products":[{"id":425539,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB32179","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"XENON","pharmForm":"MEDICINAL GAS, LIQUEFIED","activeSubstanceName":"XENON","euSubstNumber":"SUB32179","productSubstances":[{"substancePk":"32179","actSubstOrigin":"-","actSubstName":"XENON","substanceEvCode":"SUB32179"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"l litre(s)","maxDailyDoseAmount":"100","doseUomTotal":"l litre(s)","maxTotalDoseAmount":"1000","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"1","otherMedicinalProduct":"Noble gas","scientificProductEvCode":"SUB32179","devices":[],"characteristics":["11"],"routes":["INHALATION USE"],"allSubstancesChemicals":false,"productName":"XENON","jsonActiveSubstanceNames":"xenon","part1MedicinalProductRoleMscInfos":[{"memberStateConcernedInfo":{"id":659,"clinicalTrialId":604,"countryOrganisationId":2011,"reportingStatusCode":"Authorised","fromDate":"2022-06-09","toDate":"2022-06-09","isProposedRms":true,"countryName":"Finland","organisationInfo":{},"trialStatus":"Authorised","trialPeriod":[{"id":36556,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36359,"trialStartDate":"2024-09-30","fromDate":"2024-09-30"},{"id":36557,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36558,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36358,"trialStartDate":"2024-09-30","fromDate":"2024-09-30"}],"trialRecruitmentPeriod":[{"id":51105,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"},{"id":51106,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"},{"id":51104,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":49044,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-10-01"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":283,"mscId":659,"trialStatus":"Under evaluation","trialStatusDate":"2022-05-30T11:23:11.053"},{"id":373,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2022-06-22T13:44:32.229"},{"id":57813,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.305"},{"id":51864,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-09-11T00:55:00.822"},{"id":57812,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.211"},{"id":51863,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-09-11T00:55:00.629"},{"id":53614,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-09-24T14:26:07.707"},{"id":57814,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.354"},{"id":57393,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-10-16T00:55:02.373"},{"id":57811,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.145"},{"id":57392,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-10-16T00:55:02.287"}],"applicationTypeMsc":"1","mscName":"Finland"},"countryOrganisationId":2011}]},{"id":425538,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"9667967","productPharmForm":"LÄÄKKEELLINEN KAASU, KRYOGEENINEN","euMpNumber":"PRD404292","marketingAuthNumber":"22087","prodAuthStatus":2,"prodName":"CONOXIA 100%  lääkkeellinen kaasu, kryogeeninen","pharmForm":"MEDICINAL GAS, CRYOGENIC","activeSubstanceName":"OXYGEN","euSubstNumber":"SUB14733MIG","authorisationCountryCode":"FI","mrpNumber":"SE/H/0607/002","nameOrg":"LINDE GAS","productSubstances":[{"productPk":"9667967","substancePk":"271562","nameOrg":"LINDE GAS","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"OXYGEN","substanceEvCode":"SUB14733MIG","synonyms":["OXYGENIUM"]}],"atcCode":"V03AN01","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"l litre(s)","maxDailyDoseAmount":"1000","doseUomTotal":"l litre(s)","maxTotalDoseAmount":"100000","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"2","evCode":"PRD404292","devices":[],"characteristics":[],"routes":["INHALATION USE"],"allSubstancesChemicals":true,"productName":"CONOXIA 100%  lääkkeellinen kaasu, kryogeeninen","jsonActiveSubstanceNames":"oxygen","part1MedicinalProductRoleMscInfos":[{"memberStateConcernedInfo":{"id":659,"clinicalTrialId":604,"countryOrganisationId":2011,"reportingStatusCode":"Authorised","fromDate":"2022-06-09","toDate":"2022-06-09","isProposedRms":true,"countryName":"Finland","organisationInfo":{},"trialStatus":"Authorised","trialPeriod":[{"id":36556,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36359,"trialStartDate":"2024-09-30","fromDate":"2024-09-30"},{"id":36557,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36558,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36358,"trialStartDate":"2024-09-30","fromDate":"2024-09-30"}],"trialRecruitmentPeriod":[{"id":51105,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"},{"id":51106,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"},{"id":51104,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":49044,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-10-01"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":283,"mscId":659,"trialStatus":"Under evaluation","trialStatusDate":"2022-05-30T11:23:11.053"},{"id":373,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2022-06-22T13:44:32.229"},{"id":57813,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.305"},{"id":51864,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-09-11T00:55:00.822"},{"id":57812,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.211"},{"id":51863,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-09-11T00:55:00.629"},{"id":53614,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-09-24T14:26:07.707"},{"id":57814,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.354"},{"id":57393,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-10-16T00:55:02.373"},{"id":57811,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.145"},{"id":57392,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-10-16T00:55:02.287"}],"applicationTypeMsc":"1","mscName":"Finland"},"countryOrganisationId":2011}],"pharmaceuticalFormDisplay":"MEDICINAL GAS, CRYOGENIC"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"Effect of xenon on brain injury, neurological outcome and survival in patients after aneurysmal subarachnoid hemorrhage","fullTitleTranslations":[{"id":8196283,"uuid":"eea31416-5625-4e69-baa6-76aea91df5e2","attributeTranslation":"Ksenonin vaikutus lukinkalvonalainen verenvuoto -potilaiden aivovaurioon, neurologiseen toipumiseen ja kuolleisuuteen","language":9,"languageDescription":"Finnish"}],"publicTitle":"Effect of xenon on brain injury, neurological outcome and survival in patients after aneurysmal subarachnoid hemorrhage","publicTitleTranslations":[{"id":8196284,"uuid":"d78d37a7-2b8c-4cb2-825d-adc7fd26312b","attributeTranslation":"Ksenonin vaikutus lukinkalvonalainen verenvuoto -potilaiden aivovaurioon, neurologiseen toipumiseen ja kuolleisuuteen","language":9,"languageDescription":"Finnish"}],"shortTitle":"T109/2019Xe-SAH","secondaryIdentifyingNumbers":{"nctNumber":{"id":439539,"number":"NCT04696523"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"4","trialCategory":"2","justificationForTrialCategory":"Phase2","trialCategoryId":93434},"medicalCondition":{"partIMedicalConditions":[{"id":106299,"medicalCondition":"Aneyrysmal subarachnoid hemorrhage needing ventilatory care in intensive care unit","medicalConditionTranslations":[],"isConditionRareDisease":false}],"meddraConditionTerms":[{"termId":100000005529,"version":"20.0","level":"HLT","termName":"Central nervous system vascular disorders NEC","classificationCode":"10007962","organClass":10029205,"active":false}]},"trialObjective":{"trialScopes":[{"code":"3","trialScopeId":308754}],"mainObjective":"To explore neuroprotective properties of xenon in patients after aneurysmal subarachnoid hemorrhage (SAH).","mainObjectiveTranslations":[],"secondaryObjectives":[{"id":355444,"number":1,"secondaryObjective":"To explore the neuroprotective effect of xenon  1. On the white matter injury in cerebellum, cerebellar peduncles, corpus callosum (genu, body, splenium), anterior ventral midbrain, cingulum, hypothalamus, and centrum semiovale","secondaryObjectiveTranslations":[]},{"id":355445,"number":2,"secondaryObjective":"On the incidence and severity of EBI (within 72 hours after start of SAH symptoms) and DCI (between day 4 and 6 weeks after start of aSAH symtoms)","secondaryObjectiveTranslations":[]},{"id":355446,"number":3,"secondaryObjective":"On the incidence of adverse events, serious adverse events and suspected unexpected serious adverse reactions (SUSARs).","secondaryObjectiveTranslations":[]},{"id":355447,"number":4,"secondaryObjective":"On the inflammatory process, i.e. microglia activation and CSF cytokine level","secondaryObjectiveTranslations":[]},{"id":355448,"number":5,"secondaryObjective":"On the need and duration of intracerebral pressure (ICP) treatments","secondaryObjectiveTranslations":[]},{"id":355449,"number":6,"secondaryObjective":"On the plasma catecholamine levels","secondaryObjectiveTranslations":[]},{"id":355450,"number":7,"secondaryObjective":"On the release of hs troponin-T","secondaryObjectiveTranslations":[]},{"id":355451,"number":8,"secondaryObjective":"On the release of neuron specific enolase (NSE), neurofilament light (NF-L), glial fibrillary acidic protein (GFAP), calcium binding protein S100B (S100B), ubiquitin carboxyterminal hydrolase L1 (UCH-L1), total tau, cytokines (tumour necrosis factor alpha, interleukins 6 and 10)","secondaryObjectiveTranslations":[]},{"id":355452,"number":9,"secondaryObjective":"The exploratory objectives are as follows:  1. To explore a predictive value of the different MRI techniques (e.g. DTI, perfusion, constrained spherical deconvolution) alone and combined for clinical outcome at 3 months, at 1 and 2 years after SAH.  2. To explore pathophysiological pathways of the post-SAH period between the two treatment groups and a predictive value of selected proteomics and metabolomics on severity of EBI and DCI and neurological outcome (i.e. good outcome: mRS 0-2 vs poor outcome: 3-6) 3. To explore a role of microglia activation on the development of DCI 4. To explore a role of cytokine level on the development of DCI 5. To explore a combination of brain imaging markers, selected biomarkers (see secondary objectives # 8), plasma metabolomics, spinal fluid metabolomics and clinical examinations (e.g. motor score, pupillary light reflex with pupillometry, epileptic seizures) as a prognostication model for EBI, DCI and neurological outcome at 3 months, at 1 and 2 years after SAH (i.e. good outcome: mRS 0-2 vs poor outcome: 3-6) 6. Applicability of brain network analysis with graph theoretical analysis and anatomical connectivity of white matter tracts in prognostic models for EBI, DCI and neurological outcome at 3 months, at 1 and 2 years after SAH (i.e. good outcome: mRS 0-2 vs poor outcome: 3-6) and to investigate xenon’s effect on the connectivity. 7. Mechanisms of developing EBI and DCI by utilizing brain imaging and metabolomics (i.e. plasma and spinal fluid) 8. Clinical neurological outcome at 3-months and at 1 year and at 2 years. 9. Development of a prognostication model for EBI and DCI and neurological outcome at 3 months and at 1 year and at 2 years after SAH","secondaryObjectiveTranslations":[]},{"id":355453,"number":10,"secondaryObjective":"Objectives related to the xenon delivery device Akzent X Color    . Safety of the xenon delivery device Akzent X Color used in the xenon group as assessed with ventilatory parameters (tidal volume, minute volume, respiratory frequency, PEEP, plateau pressure, peak pressure, lung compliance, inspiratory O2 %, end-tidal CO2), blood gas values, frequency and type of adverse events (AE) and serious events (SAE) related to the performance of the ventilators (see details of assessing and reporting of AEs and SAEs in 22.4). Safety parameters will be compared between the control group and the xenon group in the interim analysis after 80 patients and in the final analysis with the complete population. A case by case performance of the device as well as safety are assessed by comparing ventilatory parameters (tidal volume, minute volume, respiratory frequency, PEEP, plateau pressure, peak pressure, lung compliance, inspiratory O2 %, end-tidal CO2) recorded by the device with the corresponding ventilatory parameters recorded simultaneously by the external CE-marked CARESCAPETM Respiratory Modules, GE Healthcare, https://www.gehealthcare.com/en-sg/-/jssmedia/9d671439697e47dfb2d8f69654449952.pdf (E-sCO, E-sCOV, E-sCOVX, E-sCAiO, E-sCAiOV, E-sCAiOVX, E-sCAioE, E-sCAiOVE), which are indicated for use with a host device for monitoring respiratory parameters (see details on page 78)","secondaryObjectiveTranslations":[]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":682876,"number":1,"principalInclusionCriteria":"To be considered eligible to participate in this study, a SAH subject must meet the inclusion criteria listed below: 1.\tInformed consent obtained from the next of kin or legal representative 2.\tAneurysmal subarachnoid hemorrhage visible on CTA or DSA. 3.\tDeterioration of consciousness to Hunt-Hess 3-5  4.\tAge of ≥ 18 years 5.\tIntubated.  6.\tGCS 3–12 obtained off neuromuscular blocking agents 7.\tXenon treatment can be started within 6 hours after loss of consciousness 8. The interval between the estimated onset of bleeding and the occurrence of loss of consciousness must not exceed 12 hours.","principalInclusionCriteriaTranslations":[]}],"principalExclusionCriteria":[{"id":1173487,"number":1,"principalExclusionCriteria":"Acute or chronic traumatic brain injury","principalExclusionCriteriaTranslations":[]},{"id":1173488,"number":10,"principalExclusionCriteria":"Current enrollment in another interventional study","principalExclusionCriteriaTranslations":[]},{"id":1173489,"number":11,"principalExclusionCriteria":"The subject is known to have clinically significant laboratory abnormality, medical condition (such as decompensated liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator’s opinion, makes it inappropriate for the subject to participate in this clinical trial","principalExclusionCriteriaTranslations":[]},{"id":1173490,"number":12,"principalExclusionCriteria":"Presence of implants or foreign bodies which are not known to be MRI safe","principalExclusionCriteriaTranslations":[]},{"id":1173491,"number":2,"principalExclusionCriteria":"Maximum diameter of intracerebral hemorrhage > 2.5 cm","principalExclusionCriteriaTranslations":[]},{"id":1173492,"number":3,"principalExclusionCriteria":"Pneumothorax or pneumomediastinum","principalExclusionCriteriaTranslations":[]},{"id":1173493,"number":4,"principalExclusionCriteria":"Acute lung injury requiring ≥ 60% FIO2 (fraction of inspired oxygen)","principalExclusionCriteriaTranslations":[]},{"id":1173494,"number":5,"principalExclusionCriteria":"Systolic arterial pressure < 80 mmHg or mean arterial pressure < 60 mmHg for over 30 min period","principalExclusionCriteriaTranslations":[]},{"id":1173495,"number":6,"principalExclusionCriteria":"Bilaterally fixed and dilated pupils","principalExclusionCriteriaTranslations":[]},{"id":1173496,"number":7,"principalExclusionCriteria":"Positive pregnancy test, known pregnancy, or current breast-feeding","principalExclusionCriteriaTranslations":[]},{"id":1173497,"number":8,"principalExclusionCriteria":"Neurological deficiency due to traumatic brain injury or other neurological illness","principalExclusionCriteriaTranslations":[]},{"id":1173498,"number":9,"principalExclusionCriteria":"Imminent death or current life-threatening disease","principalExclusionCriteriaTranslations":[]}]},"endPoint":{"primaryEndPoints":[{"id":799758,"number":1,"endPoint":"Primary endpoint: Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly higher in the xenon group than in the control group as assessed with the 1st MRI.","isPrimary":true,"endPointTranslations":[]}],"secondaryEndPoints":[{"id":799759,"number":1,"endPoint":"Fractional anisotropy of white matter at cerebellum, cerebellar peduncles, hypothalamus, anterior ventral midbrain, cingulum, centrum semiovale and/or at corpus callosum (genu, body, splenium) as assessed with the 1st MRI.","isPrimary":false,"endPointTranslations":[]},{"id":799760,"number":2,"endPoint":"Safety and tolerability of xenon as assessed with a ratio of adverse events, serious adverse events and suspected unexpected serious adverse reactions (SUSARs) during the follow-up of one year between the xenon group and the control group.","isPrimary":false,"endPointTranslations":[]},{"id":799761,"number":3,"endPoint":"Composite of radiological EBI (within 72 hours after start of SAH symptoms) and DCI (Criterion of DCI","isPrimary":false,"endPointTranslations":[]},{"id":799762,"number":4,"endPoint":"Neurogenic Stress Cardiomyopathy and Stunned Myocardium","isPrimary":false,"endPointTranslations":[]},{"id":799763,"number":5,"endPoint":"ICP level up to 14 days after onset of aSAH symptoms","isPrimary":false,"endPointTranslations":[]},{"id":799764,"number":6,"endPoint":"Need for ICP therapies up to 14 days after onset of aSAH symptoms (hypothermia, decompressive craniotomy)","isPrimary":false,"endPointTranslations":[]},{"id":799765,"number":7,"endPoint":"Duration of therapy for ICP control/monitoring up to 14 days after onset of aSAH symptoms","isPrimary":false,"endPointTranslations":[]},{"id":799766,"number":8,"endPoint":"Plasma catecholamine level","isPrimary":false,"endPointTranslations":[]},{"id":799767,"number":9,"endPoint":"Difference of neuron specific enolase (NSE), neurofilament light (NF-L), glial fibrillary acidic protein (GFAP), calcium binding protein S100B (S100B), ubiquitin carboxyterminal hydrolase L1 (UCH-L1), total tau, cytokines (tumour necrosis factor alpha, interleukins 6 and 10) between xenon and control group and in predicting risk for EBI within first 72 hours after start of aSAH symptoms , vasospasm (within 21 days after start of SAH symptoms) and DCI (between day 4 and 6 weeks after start of SAH","isPrimary":false,"endPointTranslations":[]},{"id":799768,"number":10,"endPoint":"Development of prognostication models with a selected combination of brain imaging, biomarkers, clinical data and metabolomics by applying artificial intelligence and machine learning for EBI within first 72 hours after start of aSAH symptoms , vasospasm (within 21 days after start of SAH symptoms) and DCI (between day 4 and 6 weeks after start of SAH symptoms ) and good neurological outcome at 3 moths, at 1 year and at 2 years after SAH (mRS 0-2).","isPrimary":false,"endPointTranslations":[]},{"id":799769,"number":11,"endPoint":"Difference of MRI parameters between xenon and control group and in predicting risk for EBI within first 72 hours after start of aSAH symptoms , vasospasm (within 21 days after start of SAH symptoms) and DCI (between day 4 and 6 weeks after start of SAH symptoms ) and good neurological outcome at 3 moths, at 1 year and at 2 years after SAH (mRS 0-2).","isPrimary":false,"endPointTranslations":[]},{"id":799770,"number":12,"endPoint":"Difference of CTA parameters between xenon and control group and in predicting risk for EBI within first 72 hours after start of aSAH symptoms , vasospasm (within 21 days after start of SAH symptoms) and DCI (between day 4 and 6 weeks after start of SAH symptoms ) and good neurological outcome at 3 moths, at 1 year and at 2 years after SAH (mRS 0-2).","isPrimary":false,"endPointTranslations":[]},{"id":799771,"number":13,"endPoint":"Difference of DSA parameters between xenon and control group and in predicting risk for EBI within first 72 hours after start of aSAH symptoms , vasospasm (within 21 days after start of SAH symptoms) and DCI (between day 4 and 6 weeks after start of SAH symptoms ) and good neurological outcome at 3 moths, at 1 year and at 2 years after SAH (mRS 0-2).","isPrimary":false,"endPointTranslations":[]},{"id":799772,"number":14,"endPoint":"Predictive value CFD simulations in predicting risk for EBI within first 72 hours after start of aSAH symptoms , vasospasm (within 21 days after start of SAH symptoms) and DCI (between day 4 and 6 weeks after start of SAH symptoms ) and good neurological outcome at 3 moths, at 1 year and at 2 years after SAH (mRS 0-2).","isPrimary":false,"endPointTranslations":[]},{"id":799773,"number":15,"endPoint":"Difference of metabolomics of plasma and spinal fluid between xenon and control group and in predicting risk for EBI within first 72 hours after start of aSAH symptoms , vasospasm (within 21 days after start of SAH symptoms) and DCI (between day 4 and 6 weeks after start of SAH symptoms ) and good neurological outcome at 3 moths, at 1 year and at 2 years after SAH (mRS 0-2).","isPrimary":false,"endPointTranslations":[]},{"id":799774,"number":16,"endPoint":"Difference of activity of microglia cells between xenon and control group and in predicting risk for DCI and good neurological outcome at 3 moths, at 1 year and at 2 years after SAH (mRS 0-2).","isPrimary":false,"endPointTranslations":[]},{"id":799775,"number":17,"endPoint":"Safety of the xenon delivery device Akzent X Color used in the xenon group as assessed with ventilator parameters, blood gas values, adverse events and serious events related to the performance of the ventilators. Safety parameters will be compared between the control group and the xenon group in the interim analysis after 80 patients and in the final analysis with the complete population.","isPrimary":false,"endPointTranslations":[]}]},"trialDuration":{"estimatedEndDate":"2035-12-01","estimatedRecruitmentStartDate":"2024-10-01"},"sourceOfMonetarySupport":[{"id":74622,"organisationName":"State Research Funding, Finland"},{"id":74623,"organisationName":"Academy of Finland"}],"populationOfTrialSubjects":{"ageRanges":[{"id":281893,"ageRangeCategoryCode":"4","ageRangeCategory":"4"},{"id":281892,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[{"id":281894,"ageRangeCategoryCode":"3","ctAgeRangeCode":"9","ageRangeCategory":"3","ctAgeRange":"9"},{"id":281895,"ageRangeCategoryCode":"4","ctAgeRangeCode":"7","ageRangeCategory":"4","ctAgeRange":"7"}],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{"planToShareIPD":"1","planDescription":"The data of this study will be available to investigators whose proposed use of the data has been approved by an independent review committee. Individual participant data that underlie the results reported in this Article will be shared (text, tables, figures, and appendices), after de-identification, along with the study protocol. These data will be available 6 months after the Article’s publication and will be available for 12 months from publication. Data can be used for individual participant data meta-analysis. Requests and proposals should be directed to timo.laitio@elisanet.fi. To gain access, data requestors will need to sign a data access agreement."}},"protocolInformation":{"studyDesign":{"periodDetails":[{"id":149781,"businessKey":"1","title":"Screening","description":"Eligibility will be investigated","blindingMethodCode":"1","blindedRoles":[{"id":149782,"code":4,"name":"Analyst"}],"blindingDetails":"Neuroradiologists and subjects will be blinded","armDetails":[{"description":"normal state-of-art treatment","title":"control","id":84489},{"description":"xenon administered for 24 hours","title":"xenon","id":84490}],"allocationMethod":"1"}]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[{"id":452699,"number":"PMID 29169472"},{"id":452698,"number":"PMID 26978207"}],"pubmedCode":["PMID 29169472","PMID 26978207"],"pubmedUrl":["https://pubmed.ncbi.nlm.nih.gov/29169472","https://pubmed.ncbi.nlm.nih.gov/26978207"]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-11-27","conclusionDate":"2025-11-27","therapeuticAreas":[{"code":"10","name":"Diseases [C] - Nervous System Diseases [C10]"}],"medicalConditions":[{"id":106299,"medicalCondition":"Aneyrysmal subarachnoid hemorrhage needing ventilatory care in intensive care unit","isConditionRareDisease":false}],"sponsors":[{"id":115416,"primary":true,"publicContacts":[{"id":340419,"type":"Public","functionalName":"Clinical trial information desk","functionalEmailAddress":"timo.laitio@tyks.fi","telephone":"+358504653201","organisation":{"id":16337,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Turku University Central Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030555","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":340420,"type":"Scientific","functionalName":"Clinical trial information desk","functionalEmailAddress":"timo.laitio@tyks.fi","telephone":"+358504653201","organisation":{"id":16337,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Turku University Central Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030555","organisationLocationStatus":"Active"}}],"thirdParties":[],"organisation":{"id":16337,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Turku University Central Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030555","organisationLocationStatus":"Active"},"addresses":[{"id":15547,"organisation":{"id":16337,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Turku University Central Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030555","organisationLocationStatus":"Active"},"address":{"addressId":15712,"oneLine":"Savitehtaankatu 1","addressLine1":"Savitehtaankatu 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Turku","postcode":"20520","country":2011,"countryName":"Finland"},"isBusinessKeyValidated":true,"businessKey":"LOC-100048113"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"Phase2","partOneTherapeuticAreas":[{"id":1003920,"therapeuticArea":{"code":"10","name":"Diseases [C] - Nervous System Diseases [C10]"}}],"productRoleGroupInfos":[{"id":320114,"comments":"XENON","productRoleCode":"1","productRoleName":"Test","products":[{"id":425539,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB32179","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"XENON","pharmForm":"MEDICINAL GAS, LIQUEFIED","activeSubstanceName":"XENON","euSubstNumber":"SUB32179","productSubstances":[{"substancePk":"32179","actSubstOrigin":"-","actSubstName":"XENON","substanceEvCode":"SUB32179"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"l litre(s)","maxDailyDoseAmount":"100","doseUomTotal":"l litre(s)","maxTotalDoseAmount":"1000","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"1","otherMedicinalProduct":"Noble gas","scientificProductEvCode":"SUB32179","devices":[],"characteristics":["11"],"routes":["INHALATION USE"],"allSubstancesChemicals":false,"productName":"XENON","jsonActiveSubstanceNames":"xenon","part1MedicinalProductRoleMscInfos":[{"memberStateConcernedInfo":{"id":659,"clinicalTrialId":604,"countryOrganisationId":2011,"reportingStatusCode":"Authorised","fromDate":"2022-06-09","toDate":"2022-06-09","isProposedRms":true,"countryName":"Finland","organisationInfo":{},"trialStatus":"Authorised","trialPeriod":[{"id":36556,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36359,"trialStartDate":"2024-09-30","fromDate":"2024-09-30"},{"id":36557,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36558,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36358,"trialStartDate":"2024-09-30","fromDate":"2024-09-30"}],"trialRecruitmentPeriod":[{"id":51105,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"},{"id":51106,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"},{"id":51104,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":49044,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-10-01"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":283,"mscId":659,"trialStatus":"Under evaluation","trialStatusDate":"2022-05-30T11:23:11.053"},{"id":373,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2022-06-22T13:44:32.229"},{"id":57813,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.305"},{"id":51864,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-09-11T00:55:00.822"},{"id":57812,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.211"},{"id":51863,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-09-11T00:55:00.629"},{"id":53614,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-09-24T14:26:07.707"},{"id":57814,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.354"},{"id":57393,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-10-16T00:55:02.373"},{"id":57811,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.145"},{"id":57392,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-10-16T00:55:02.287"}],"applicationTypeMsc":"1","mscName":"Finland"},"countryOrganisationId":2011}]}]},{"id":320113,"comments":"CONOXIA 100%  lääkkeellinen kaasu, kryogeeninen","productRoleCode":"2","productRoleName":"Comparator","products":[{"id":425538,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"9667967","productPharmForm":"LÄÄKKEELLINEN KAASU, KRYOGEENINEN","euMpNumber":"PRD404292","marketingAuthNumber":"22087","prodAuthStatus":2,"prodName":"CONOXIA 100%  lääkkeellinen kaasu, kryogeeninen","pharmForm":"MEDICINAL GAS, CRYOGENIC","activeSubstanceName":"OXYGEN","euSubstNumber":"SUB14733MIG","authorisationCountryCode":"FI","mrpNumber":"SE/H/0607/002","nameOrg":"LINDE GAS","productSubstances":[{"productPk":"9667967","substancePk":"271562","nameOrg":"LINDE GAS","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"OXYGEN","substanceEvCode":"SUB14733MIG","synonyms":["OXYGENIUM"]}],"atcCode":"V03AN01","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"l litre(s)","maxDailyDoseAmount":"1000","doseUomTotal":"l litre(s)","maxTotalDoseAmount":"100000","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"2","evCode":"PRD404292","devices":[],"characteristics":[],"routes":["INHALATION USE"],"allSubstancesChemicals":true,"productName":"CONOXIA 100%  lääkkeellinen kaasu, kryogeeninen","jsonActiveSubstanceNames":"oxygen","part1MedicinalProductRoleMscInfos":[{"memberStateConcernedInfo":{"id":659,"clinicalTrialId":604,"countryOrganisationId":2011,"reportingStatusCode":"Authorised","fromDate":"2022-06-09","toDate":"2022-06-09","isProposedRms":true,"countryName":"Finland","organisationInfo":{},"trialStatus":"Authorised","trialPeriod":[{"id":36556,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36359,"trialStartDate":"2024-09-30","fromDate":"2024-09-30"},{"id":36557,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36558,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36358,"trialStartDate":"2024-09-30","fromDate":"2024-09-30"}],"trialRecruitmentPeriod":[{"id":51105,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"},{"id":51106,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"},{"id":51104,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":49044,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-10-01"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":283,"mscId":659,"trialStatus":"Under evaluation","trialStatusDate":"2022-05-30T11:23:11.053"},{"id":373,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2022-06-22T13:44:32.229"},{"id":57813,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.305"},{"id":51864,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-09-11T00:55:00.822"},{"id":57812,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.211"},{"id":51863,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-09-11T00:55:00.629"},{"id":53614,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-09-24T14:26:07.707"},{"id":57814,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.354"},{"id":57393,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-10-16T00:55:02.373"},{"id":57811,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.145"},{"id":57392,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-10-16T00:55:02.287"}],"applicationTypeMsc":"1","mscName":"Finland"},"countryOrganisationId":2011}],"pharmaceuticalFormDisplay":"MEDICINAL GAS, CRYOGENIC"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":177161,"mscId":659,"mscInfo":{"id":659,"clinicalTrialId":604,"countryOrganisationId":2011,"reportingStatusCode":"Authorised","fromDate":"2022-06-09","toDate":"2022-06-09","isProposedRms":true,"countryName":"Finland","organisationInfo":{},"firstDecisionDate":"2022-06-22","trialStatus":"Authorised","trialPeriod":[{"id":36556,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36359,"trialStartDate":"2024-09-30","fromDate":"2024-09-30"},{"id":36557,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36558,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},{"id":36358,"trialStartDate":"2024-09-30","fromDate":"2024-09-30"}],"trialRecruitmentPeriod":[{"id":51105,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"},{"id":51106,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"},{"id":51104,"recruitmentStartDate":"2024-10-01","fromDate":"2024-10-18"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":49044,"trialStartDate":"2024-10-01","fromDate":"2024-10-01"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-10-01"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":283,"mscId":659,"trialStatus":"Under evaluation","trialStatusDate":"2022-05-30T11:23:11.053"},{"id":373,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2022-06-22T13:44:32.229"},{"id":57813,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.305"},{"id":51864,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-09-11T00:55:00.822"},{"id":57812,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.211"},{"id":51863,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-09-11T00:55:00.629"},{"id":53614,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-09-24T14:26:07.707"},{"id":57814,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.354"},{"id":57393,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-10-16T00:55:02.373"},{"id":57811,"mscId":659,"trialStatus":"Authorised","trialStatusDate":"2024-10-18T10:17:44.145"},{"id":57392,"mscId":659,"trialStatus":"Expired","trialStatusDate":"2024-10-16T00:55:02.287"}],"applicationTypeMsc":"1","mscName":"Finland","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-03-28","decision":"authorized","decisionDate":"2022-06-22"},"decisionDate":"2022-06-22","recruitmentSubjectCount":160,"trialSites":[{"id":1141114,"organisationAddressInfo":{"id":16840,"organisation":{"id":17666,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Turku University Central Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030555","organisationLocationStatus":"Active"},"address":{"addressId":17043,"oneLine":"Savitehtaankatu 1","addressLine1":"Savitehtaankatu 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Turku","postcode":"20520","country":2011,"countryName":"Finland"},"phone":"+358504653201","email":"timo.laitio@elisanet.fi","isBusinessKeyValidated":true,"businessKey":"LOC-100048113"},"personInfo":{"id":1275684,"firstName":"Timo","lastName":"Laitio","telephone":"+358504653201","email":"timo.laitio@elisanet.fi","title":"2"},"departmentName":"Perioperative Services, Intensive Care Medicine and Pain Management"},{"id":1141113,"organisationAddressInfo":{"id":16842,"organisation":{"id":17668,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Tampere University Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009144","organisationLocationStatus":"Active"},"address":{"addressId":17045,"oneLine":"Biokatu 12 5 6","addressLine1":"Biokatu 12 5 6","addressLine2":"","addressLine3":"","addressLine4":"","city":"Tampere","postcode":"33520","country":2011,"countryName":"Finland"},"phone":"+358505321288","email":"Jaakko.langsjo@pshp.fi","isBusinessKeyValidated":true,"businessKey":"LOC-100017342"},"personInfo":{"id":1275683,"firstName":"Jaakko","lastName":"Långsjö","telephone":"+358505321288","email":"Jaakko.langsjo@pshp.fi","title":"1"},"departmentName":"Department of Anesthesiology and Intensive Care"},{"id":1141115,"organisationAddressInfo":{"id":16844,"organisation":{"id":17670,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Kuopio University Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028644","organisationLocationStatus":"Active"},"address":{"addressId":17047,"oneLine":"P. O. Box 1777","addressLine1":"P. O. Box 1777","addressLine2":"","addressLine3":"","addressLine4":"","city":"Kuopio","postcode":"70211","country":2011,"countryName":"Finland"},"phone":"+358407528283","email":"stepani.bendel@kuh.fi","isBusinessKeyValidated":true,"businessKey":"LOC-100050933"},"personInfo":{"id":1275685,"firstName":"Stepani","lastName":"Bendel","telephone":"+358407528283","email":"stepani.bendel@kuh.fi","title":"1"},"departmentName":"Department of Anesthesiology and Intensive Care"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":608,"type":"INITIAL","status":"Authorised","ctNumber":"2022-500596-32-00","trialStatus":"Authorised","submissionDate":"2022-05-30","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2022-06-21"},"partIIInfo":[{"id":1519,"mscId":659,"mscInfo":{"id":659,"mscName":"Finland","countryOrganisationId":2011,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2022-06-16","decision":"authorized","decisionDate":"2022-06-22","reportingStatusCode":"Authorised","countryName":"Finland","trialStatus":"Authorised","firstDecisionDate":"2022-06-22"},"applicationStatusCode":"Authorised"}],"decisionDate":"2022-06-22","ctMSCsByApplication":[{"id":659,"mscName":"Finland","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":42,"applicationId":608,"mscId":659,"mscName":"Finland","decisionDate":"2022-06-22T13:44:32.4","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":1519,"part1Id":1219,"applicationType":"INITIAL","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"7ca9faec-8143-48dc-a016-93a3aaf0237f","productRoleGroupId":2084},{"documentUuid":"ef806a3f-dab1-48e2-8e82-1d30daa64fdd","productRoleGroupId":2084},{"documentUuid":"c3ff2e9f-8ae3-433b-94e2-0f29ebbaedb6","productRoleGroupId":2083}]},{"id":4283,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2022-500596-32-00","trialStatus":"Authorised","submissionDate":"2023-03-14","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2023-06-05"},"partIIInfo":[{"id":10010,"mscId":659,"mscInfo":{"id":659,"mscName":"Finland","countryOrganisationId":2011,"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2023-05-25","decision":"authorized","decisionDate":"2022-06-22","reportingStatusCode":"Authorised","countryName":"Finland","trialStatus":"Authorised","firstDecisionDate":"2022-06-22"},"applicationStatusCode":"Authorised"}],"decisionDate":"2023-06-06","ctMSCsByApplication":[{"id":659,"mscName":"Finland","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":2864,"applicationId":4283,"mscId":659,"mscName":"Finland","decisionDate":"2023-06-06T13:21:43.039","decision":"authorized_conditions","assessmentOutcome":"acceptable_conditions","eventType":"decision","part2Id":10010,"part1Id":5491,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"797223f3-f64e-444f-8d16-64c127e070a6","productRoleGroupId":17285},{"documentUuid":"c3ff2e9f-8ae3-433b-94e2-0f29ebbaedb6","productRoleGroupId":13362}]},{"id":16340,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2022-500596-32-00","trialStatus":"Authorised","submissionDate":"2023-11-30","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2023-06-05"},"partIIInfo":[{"id":54790,"mscId":659,"mscInfo":{"id":659,"mscName":"Finland","countryOrganisationId":2011,"decision":"authorized","decisionDate":"2022-06-22","reportingStatusCode":"Authorised","countryName":"Finland","trialStatus":"Authorised","firstDecisionDate":"2022-06-22"},"applicationStatusCode":"Authorised"}],"decisionDate":"2023-11-30","ctMSCsByApplication":[{"id":659,"mscName":"Finland","reportingStatusCode":"Authorised"}],"businessKey":"NSM-1","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":9382,"applicationId":16340,"mscId":659,"mscName":"Finland","decisionDate":"2023-11-30T11:18:02.106","decision":"authorized","eventType":"decision","part2Id":54790,"part1Id":23775,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"797223f3-f64e-444f-8d16-64c127e070a6","productRoleGroupId":69895},{"documentUuid":"c3ff2e9f-8ae3-433b-94e2-0f29ebbaedb6","productRoleGroupId":69896}]},{"id":27227,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2022-500596-32-00","trialStatus":"Authorised","submissionDate":"2024-05-28","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-06-05"},"partIIInfo":[{"id":103552,"mscId":659,"mscInfo":{"id":659,"mscName":"Finland","countryOrganisationId":2011,"decision":"authorized","decisionDate":"2022-06-22","reportingStatusCode":"Authorised","countryName":"Finland","trialStatus":"Authorised","firstDecisionDate":"2022-06-22"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-06-05","ctMSCsByApplication":[],"businessKey":"SM-3","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":24098,"applicationId":27227,"mscId":659,"mscName":"Finland","decisionDate":"2024-06-05T15:04:52.676","decision":"authorized","eventType":"decision","part1Id":40912,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"797223f3-f64e-444f-8d16-64c127e070a6","productRoleGroupId":126277},{"documentUuid":"c3ff2e9f-8ae3-433b-94e2-0f29ebbaedb6","productRoleGroupId":126276}]},{"id":33742,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2022-500596-32-00","trialStatus":"Authorised","submissionDate":"2024-08-21","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-09-30"},"partIIInfo":[{"id":130142,"mscId":659,"mscInfo":{"id":659,"mscName":"Finland","countryOrganisationId":2011,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-09-16","decision":"authorized","decisionDate":"2022-06-22","reportingStatusCode":"Authorised","countryName":"Finland","trialStatus":"Authorised","firstDecisionDate":"2022-06-22"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-09-30","ctMSCsByApplication":[{"id":659,"mscName":"Finland","reportingStatusCode":"Authorised"}],"businessKey":"SM-6","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":39664,"applicationId":33742,"mscId":659,"mscName":"Finland","decisionDate":"2024-09-30T08:18:24.482","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":130142,"part1Id":51512,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"797223f3-f64e-444f-8d16-64c127e070a6","productRoleGroupId":161287},{"documentUuid":"c3ff2e9f-8ae3-433b-94e2-0f29ebbaedb6","productRoleGroupId":161288}]},{"id":46939,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2022-500596-32-00","trialStatus":"Authorised","submissionDate":"2025-03-06","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-03-31"},"partIIInfo":[{"id":177161,"mscId":659,"mscInfo":{"id":659,"mscName":"Finland","countryOrganisationId":2011,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-03-28","decision":"authorized","decisionDate":"2022-06-22","reportingStatusCode":"Authorised","countryName":"Finland","trialStatus":"Authorised","firstDecisionDate":"2022-06-22"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-04-02","ctMSCsByApplication":[{"id":659,"mscName":"Finland","reportingStatusCode":"Authorised"}],"businessKey":"SM-7","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":64848,"applicationId":46939,"mscId":659,"mscName":"Finland","decisionDate":"2025-04-02T14:07:06.425","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":177161,"part1Id":72479,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"797223f3-f64e-444f-8d16-64c127e070a6","productRoleGroupId":226569},{"documentUuid":"c3ff2e9f-8ae3-433b-94e2-0f29ebbaedb6","productRoleGroupId":226568}]},{"id":66696,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2022-500596-32-00","trialStatus":"Authorised","submissionDate":"2025-10-31","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-11-27"},"partIIInfo":[],"decisionDate":"2025-12-02","ctMSCsByApplication":[{"id":659,"mscName":"Finland","reportingStatusCode":"Authorised"}],"businessKey":"SM-8","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":100521,"applicationId":66696,"mscId":659,"mscName":"Finland","decisionDate":"2025-12-02T12:27:20.307","decision":"authorized","eventType":"decision","part1Id":102812,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"797223f3-f64e-444f-8d16-64c127e070a6","productRoleGroupId":320114},{"documentUuid":"c3ff2e9f-8ae3-433b-94e2-0f29ebbaedb6","productRoleGroupId":320113}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Finland","mscId":659,"firstDecisionDate":"2022-06-22T13:44:32.4","lastDecisionDate":"2025-04-02T14:07:06.425","mscPublicStatusCode":4}],"eudraCt":{"isTransitioned":true,"eudraCtCode":"2019-001542-17"}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":659,"mscName":"Finland","events":[{"notificationType":"START_OF_TRIAL","date":"2024-10-01"},{"notificationType":"START_OF_RECRUITMENT","date":"2024-10-01"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"liite 7&#43;suostumuksen saamisen menettelyt","uuid":"e38ac821-9dc0-4f94-8ba9-ed8b54266f80","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1","systemVersion":"1"},{"title":"tutkittavan tiedote v 1 piste 2","uuid":"55d679eb-96fb-479c-9198-173f2ff443dc","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1","systemVersion":"1"},{"title":"tutkittavan suostumus versio 1piste1","uuid":"b6fd8111-559d-4cc0-bdb1-d862af6f0dec","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1","systemVersion":"1"},{"title":"omaistiedote versio 1piste2","uuid":"bc82b1f5-672b-4dc6-8135-7b64d75e7d6e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1","systemVersion":"1"},{"title":"suostumus omainen versio 1piste1","uuid":"23b517dd-3264-4b8c-97a4-297bfd724b3f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1","systemVersion":"1"},{"title":"tutkittavan tiedote v 1 piste 3 Amendment 3","uuid":"5afcb8f5-d7a0-4d4c-8c55-9ecc1854a979","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1","systemVersion":"1"},{"title":"Omaistiedote versio 1piste3 Amendment 3","uuid":"03865f8d-eeb8-4276-8d70-4757f8e7f26e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1","systemVersion":"1"},{"title":"tutkittavan tiedote v 1 piste 4 Amendment 3","uuid":"e2341858-de3e-43f8-90da-bdec6c61e616","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1","systemVersion":"1"},{"title":"Omaistiedote versio 1piste4 Amendment 3","uuid":"993a73a4-956b-471c-907e-2b128396944c","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1","systemVersion":"1"},{"title":"tutkittavan tiedote_v1piste4_Amendment 5","uuid":"fda27da9-b80e-40e3-99a9-243ca822b866","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1","systemVersion":"1"},{"title":"Omaistiedote versio_v1piste4_Amendment 5","uuid":"42fed063-367e-4710-9bf5-393e8185bbd4","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1","systemVersion":"1"},{"title":"tutkittavan tiedote_v1piste5_Amendment 6","uuid":"222805a4-17e2-4b5b-a5f8-dff93bb5874d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1.5","systemVersion":"1"},{"title":"Omaistiedote versio_v1piste5_Amendment 6","uuid":"bf0a74a0-b22a-4b9b-bad3-944ec5b3a4a6","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"DOC","associatedEntityId":177161,"manualVersion":"1.5","systemVersion":"1"},{"title":"CLINICAL STUDY PROTOCOL","uuid":"55520fa2-b492-4141-9f12-6f7ec0ee1c19","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"DOCX","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"CLINICAL STUDY PROTOCOL XeSAH versio 1piste3 Amendment 3","uuid":"b3c02050-2236-4d1f-933d-ccc554e6f3b8","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"DOCX","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"Clinical Study Protocol_vs1piste4_Amendment 5_muuotkset merkitty","uuid":"2693df93-b7cf-4c34-b306-8d6f1d4f17c8","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"DOCX","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"Clinical Study Protocol_vs1piste4_Amendment 5_clean copy","uuid":"af89ceb2-1060-4fdc-b052-37f02da1760f","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"DOCX","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"Liite 4_CLINICAL STUDY PROTOCOL XeSAH versio 1piste4_DMD FIMEA_submitted","uuid":"b8e9a985-b37c-4ffd-a01b-10f61581bb28","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"DOCX","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"Clinical Study Protocol_vs1piste5_Amendment 6","uuid":"038a841f-adfa-4c29-aba0-4ebe0b1bf1e5","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"DOCX","associatedEntityId":102812,"manualVersion":"1.5","systemVersion":"1"},{"title":"Clinical Study Protocol_vs1piste6_Amendment 7","uuid":"8254bc48-ad59-4e64-8202-c9ee92bd99e7","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"DOCX","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"APPENDIX 1 Operating instructions GA Akzent X Color","uuid":"6910cff9-796e-4ce4-86d9-30d479a41ec8","documentType":"6","documentTypeLabel":"Protocol - Extract (for publication)","fileType":"PDF","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"APPENDIX 2 AA Softwareupdate Akzent X Color","uuid":"9fc3ce47-73c8-4488-849a-fa07297a5783","documentType":"6","documentTypeLabel":"Protocol - Extract (for publication)","fileType":"PDF","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"APPENDIX 3 EN 6060 1 2 2007 EMC TEST REPORT","uuid":"8905a6bd-aa27-4aa7-b023-3f3d2099cba0","documentType":"6","documentTypeLabel":"Protocol - Extract (for publication)","fileType":"PDF","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"Synopsis","uuid":"46aa0393-0855-49c0-af30-1b9445827451","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"DOCX","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"SYNOPSIS Amendment 3","uuid":"bfea5905-10fa-48b5-bc81-62d2379635b6","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"DOCX","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"liite 5_Yhteenveto suomeksi","uuid":"bf37b54c-67af-4bce-b227-c4a4f24409c8","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"DOC","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"SYNOPSIS_Amendment 6","uuid":"f2900097-124b-4cbb-80fa-8d7a38c69818","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"DOCX","associatedEntityId":102812,"manualVersion":"1.5","systemVersion":"1"},{"title":"Yhteenveto suomeksi_Amendment 6","uuid":"9d027638-963f-48f2-aac0-8dee7ee92acc","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"DOC","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"SYNOPSIS_Amendment 7","uuid":"d0b68690-fa39-4772-b42a-b4bec8e27f53","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"DOCX","associatedEntityId":102812,"manualVersion":"1","systemVersion":"1"},{"title":"APPENDIX A xenon_safety data sheet Linde BOC","uuid":"797223f3-f64e-444f-8d16-64c127e070a6","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":320114,"manualVersion":"1","systemVersion":"1"},{"title":"SPC Conoxia","uuid":"c3ff2e9f-8ae3-433b-94e2-0f29ebbaedb6","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":320113,"manualVersion":"1","systemVersion":"1"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}